BIIB250103C200000
- 0.00
- 0.000.00%
Biogen Newsroom
Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic
Guggenheim Adjusts Price Target on Biogen to $190 From $245, Maintains Buy Rating
Biogen Shares Lower After Piper Sandler Downgrade
17 Analysts Assess Biogen: What You Need To Know
Biogen Price Target Cut to $138.00/Share From $315.00 by Piper Sandler
Biogen Analyst Ratings
Express News | Piper Sandler has downgraded Biogen's rating to neutral.
These Battered S&P 500 Stocks Could Be Ripe for a Turnaround in 2025
Express News | Biogen : Piper Sandler Cuts to Neutral From Overweight
Why Biogen Inc. (BIIB) Is a Top Value Stock for the Long-Term
The U.S. stock market officially closed for 2024! Among the components of the three major stock indices, who performed the best and who performed the worst?
AppLovin, a constituent stock of the Nasdaq, surged by 713%, becoming the biggest dark horse, with an increase more than four times that of AI leader NVIDIA.
These Are the Best and Worst Stocks This Year
Biogen Inc. (BIIB): Among the Cheap Healthcare Stocks to Buy Heading Into 2025
Express News | Eli Lilly and Co has launched a new drug for Alzheimer's disease: annual medication costs exceed 0.03 million dollars. Pfizer and Roche are making arrangements.
Investors Aren't Entirely Convinced By Biogen Inc.'s (NASDAQ:BIIB) Earnings
2024's Top and Bottom Nasdaq-100 Performers Includes NVDA, APP, INTC, MRNA, and More
Biogen Faces Multiple Analyst Downgrades in December 2024
BMO Capital has lowered the Target Price and rating for Bojian.
GeLong Hui December 23 | BMO Capital: Adjusted the Target Price for Bojien from 230 dollars to 164 dollars, and downgraded the rating from "Outperform" to "Market Perform." (GeLong Hui)
How to find the "alpha" market in U.S. stocks next year? Goldman Sachs provides an investment guide.
Zhihui Finance has learned that Goldman Sachs analysts said in a report that over the next six months, the materials, Software, and services industries in the USA are most likely to outperform the Large Cap. Goldman Sachs strategist David Kostin stated in a report on December 20 that they introduced a model for USA Stocks to select industries expected to exceed the benchmark Index by 5 percentage points or more, "to identify 'high conviction' views with significant Alpha potential." He noted, "Our model incorporates macro, fundamental, and valuation data as independent variables. We run probability models separately for each Industry, only including
SA Asks: Which Big Pharmas Are Likely to Announce Big M&A Deals?